Comparison of all renal replacement therapy modalities in terms of COVID-19 infection rate & mortality in the COVID-19 pandemic and importance of home therapies.
Serdar Kahvecioglu, Nurhan Bilen, Huseyin Celik, Cuma Bulent Gul, Mehmet Usta, Nimet Aktaş, Yusuf Bilen
{"title":"Comparison of all renal replacement therapy modalities in terms of COVID-19 infection rate & mortality in the COVID-19 pandemic and importance of home therapies.","authors":"Serdar Kahvecioglu, Nurhan Bilen, Huseyin Celik, Cuma Bulent Gul, Mehmet Usta, Nimet Aktaş, Yusuf Bilen","doi":"10.1111/1744-9987.13930","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the infection rate and infection-related mortality among all renal replacement therapies during the COVID-19 pandemics.</p><p><strong>Methods: </strong>One thousand three hundred thirty-six end-stage renal disease (ESRD) patients who had applied for renal replacement therapy between March 2020 and January 2021 were included in the study. COVID-19 infection and mortality rates were compared between patient groups.</p><p><strong>Results: </strong>The COVID-19 infection rate in the whole study group was 13.12% (n: 178). The highest infection rate was in the center hemodialysis, 16.33% (n: 139). There was no COVID-19 infection in home hemodialysis (HHD). Mortality rate was 2.87% (n: 39) in the whole cohort and 3.87% (n: 33) in center hemodialysis (CHD), 1.47% (n:5) in kidney transplant (Tx), and 0.81% (n: 1) in the peritoneal dialysis (PD) group. COVID-19 infection rate of home replacement therapy (HRT) (n: 39) patients was significantly lower than CHD (n: 139) (p < 0.001).</p><p><strong>Conclusion: </strong>The COVID-19 infection rate and mortality were significantly lower than those of CHD in all home-based modalities subgroups.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538799/pdf/TAP-9999-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.13930","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This study aimed to compare the infection rate and infection-related mortality among all renal replacement therapies during the COVID-19 pandemics.
Methods: One thousand three hundred thirty-six end-stage renal disease (ESRD) patients who had applied for renal replacement therapy between March 2020 and January 2021 were included in the study. COVID-19 infection and mortality rates were compared between patient groups.
Results: The COVID-19 infection rate in the whole study group was 13.12% (n: 178). The highest infection rate was in the center hemodialysis, 16.33% (n: 139). There was no COVID-19 infection in home hemodialysis (HHD). Mortality rate was 2.87% (n: 39) in the whole cohort and 3.87% (n: 33) in center hemodialysis (CHD), 1.47% (n:5) in kidney transplant (Tx), and 0.81% (n: 1) in the peritoneal dialysis (PD) group. COVID-19 infection rate of home replacement therapy (HRT) (n: 39) patients was significantly lower than CHD (n: 139) (p < 0.001).
Conclusion: The COVID-19 infection rate and mortality were significantly lower than those of CHD in all home-based modalities subgroups.
期刊介绍:
Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.